The U.S. Food and Drug Administration (FDA) has agreed to review Verastem Oncology’s application seeking approval of a combination of avutometinib and defactinib for…
News
Minimal residual disease or MRD — defined as a very small number of cancer cells that remain in the body during or after treatment —…
Treatment with the antipsychotic medication clozapine may increase the risk of blood cancers, but their overall likelihood is still low in people taking the drug,…
PANCREATIC CANCER
Fluorescent dye assists in surgical removal of small pancreatic tumors
Fluorescent imaging can safely help surgeons find and remove small tumors in the pancreas, according to a recent report. The case study describes how the…
Chimerix has submitted an application asking the U.S. Food and Drug Administration (FDA) to approve its oral therapy dordaviprone as a treatment for recurrent…
PANCREATIC CANCER
Elraglusib can prolong survival in metastatic pancreatic cancer: Trial
Adding elraglusib, a small molecule being developed by Actuate Therapeutics, to standard chemotherapy with gemcitabine and nab-paclitaxel (GnP) as a first-line treatment for metastatic…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to the anti-cancer agent THIO as a potential treatment for an uncommon…
GYNECOLOGICAL CANCER
Gut microbiome tied to therapy response in recurrent ovarian cancer
A person’s microbiome, or the collection of all microorganisms that live in the gut, can enhance the body’s antitumor response and lead to better treatment…
Most people with relapsed or refractory multiple myeloma (RRMM) given the cell therapy anitocabtagene autoleucel — known as anito-cel — in a Phase 2…
Treatment with Zynlonta (loncastuximab tesirine) is helping to push high-risk follicular lymphoma and marginal zone lymphoma into complete remission for a majority of the…
Recent Posts
- Oral treatment for ovarian cancer put on FDA fast track
- J&J seeks approval in EU of Tecvayli-Darzalex for hard-to-treat myeloma
- I have goals and aspirations — not New Year’s resolutions
- 1st 4 patients in AML treatment combo trial show response
- FDA grants orphan drug status to ARB1002 for pancreatic cancer
